A major Cochrane review found that drugs designed to target amyloid beta protein in the brain are unlikely to provide meaningful benefit to patients. At the same time, these treatments appear to increase the risk of brain swelling and bleeding.
Amyloid beta is a protein that accumulates in the brains of Alzheimer’s patients years before symptoms appear. Scientists have long believed that removing these protein deposits can slow or prevent disease. Based on this idea, several drugs have been developed to remove amyloid from the brain.
Large-scale review of Alzheimer’s disease drug trials
The new analysis combined results from 17 clinical trials involving 20,342 participants. All studies focused on people with mild cognitive impairment or early stages of Alzheimer’s dementia. Researchers suggest that targeting amyloid in the early stages of the disease may offer the best chance of slowing progression.
Effects are below meaningful clinical thresholds
The results showed that anti-amyloid drugs had no or very small effect on memory decline and the severity of dementia. In fact, the measured effects were far below the level that would be considered meaningful for patients in clinical practice.
“Unfortunately, the evidence suggests that these drugs do not produce significant changes in patients,” says lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neuroscience in Bologna, Italy. “There is now a compelling body of evidence converging on the conclusion that there is no clinically meaningful effect. Early trials have shown statistically significant results, but it is important to distinguish this from clinical relevance. Trials often show statistically significant results that do not translate into clinically meaningful differences for patients.”
Brain swelling and increased risk of bleeding
This review found not only no benefits, but also safety concerns. Anti-amyloid drugs are associated with a higher likelihood of brain swelling and bleeding. In many cases, these changes were only visible on brain scans and did not cause any obvious symptoms. However, long-term effects remain uncertain because symptoms are reported differently in different studies.
Rethinking the future of Alzheimer’s disease treatment
Based on these results, the researchers concluded that continuing to focus on removing amyloid beta is unlikely to lead to significant improvement in patients. These drugs reduce amyloid levels in the brain, but this does not seem to lead to better results.
The authors suggest that future research should shift to other biological pathways involved in Alzheimer’s disease. Many studies have already explored alternative approaches.
“I see patients with Alzheimer’s disease every week in the clinic, and I wish we could provide them with an effective treatment,” said lead author Ed Richard, professor of neurology at Radboud University Medical Center. “While existing approved drugs provide some benefit for some patients, there remains a high unmet need for more effective treatments. Unfortunately, anti-amyloid drugs do not provide this and come with additional risks. Given the lack of correlation between amyloid clearance and clinical benefit, we need to explore other routes to help address this devastating disease.”
